Investigating and comparing the severity and prevalence of ventilator-induced pneumonia in patients taking famotidine and pantoprazole in the intensive care unit

To determine the effects of famotidine and pantoprazole on the incidence of ventilator-induced pneumonia in the intensive care unit.

This prospective experimental study will be conducted as a randomized clinical trial. The study population in this study will be patients hospitalized in the intensive care unit of Tehran Bou-Ali Hospital in 1403 who use mechanical ventilation.

Eligible patients will be assigned to two treatment groups by a random block method of four by the attending physician. One group will be treated with a stress ulcer prophylaxis regimen with intravenous pantoprazole 40 mg daily and the second group with a stress ulcer prophylaxis regimen with intravenous famotidine 20 mg twice a day. Pneumonia assessment will also be based on the criteria provided by the ATS/IDSA and CDC guidelines.

The inclusion criteria for the study include the use of patients aged 18 to 80 years in intensive care units who have mechanical ventilation for at least 48 hours. Patients with active pulmonary infection, patients with immunosuppression, patients with liver problems, renal (high creatinine levels), people with a history of sensitivity, and those with active gastrointestinal bleeding will not be included.

One group will be treated with the stress ulcer prophylaxis regimen with intravenous pantoprazole 40 mg daily and the second group will be treated with the stress ulcer prophylaxis regimen with intravenous famotidine 20 mg twice daily.

Incidence of pneumonia, which is measured by the occurrence of infection and non-occurrence of pneumonia infection.

Patients will be randomly assigned to two groups receiving Pantoprazole (A) and Famotidine (B). The permutations of the block will thus be BBAA-BAAB-BABA-ABBA-ABBAAB. Each block will be numbered from one to six, then a random number will be selected from one to six. Corresponding the extracted number of the target block will be extracted and according to its permutations, patients will be assigned to two groups of treatment Pantoprazole (A) and Famotidine (B) treatment group. Selection of patients and allocating patients to study groups and drug interventions will be performed by the physician. Data extracted from each patient will be done by the researcher and based on the form.

The two study groups are placed according to the existing guidelines for stress ulcer prophylaxis. The patient will not know the type of prophylaxis regimen, and the researcher will not know the type of treatment received by the patients until the end of the sampling and decoding of the drugs. As a result, the study is done in a double-blind manner.

The personal data of people is received and recorded confidentially and with their informed consent.

Access is possible after the publication of the article.

All researchers can access the data by searching the global databases after the publication of the article.

No more information

Applicants can refer to the Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Dr. Amirhossein Ghanbarzamani, or contact the researcher by sending an email to omidi.san@gmail.com

Applicants can apply for research information by visiting the department or by contacting the e-mail address and telephone number as well as providing information on academic studies and the purpose of requesting the information. Applicants must commit themselves to mention the source. If the request is sent six months after the publication of the research information, there searcher will send the data to the requesting party by email within a week.